Cargando…
COVID-19: Epidemiologische und klinische Fakten
Until July 31, 2020, about 17.6 million SARS-CoV‑2 infections and 680,000 deaths from COVID-19 were reported. SARS-CoV‑2 is most likely transmitted by droplets and probably by aerosols. Patients become infectious 2–3 days before the onset of symptoms, and persons with asymptomatic infections are als...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456747/ https://www.ncbi.nlm.nih.gov/pubmed/32865603 http://dx.doi.org/10.1007/s00117-020-00741-y |
_version_ | 1783575855523430400 |
---|---|
author | Hemmer, Christoph J. Geerdes-Fenge, Hilte F. Reisinger, Emil C. |
author_facet | Hemmer, Christoph J. Geerdes-Fenge, Hilte F. Reisinger, Emil C. |
author_sort | Hemmer, Christoph J. |
collection | PubMed |
description | Until July 31, 2020, about 17.6 million SARS-CoV‑2 infections and 680,000 deaths from COVID-19 were reported. SARS-CoV‑2 is most likely transmitted by droplets and probably by aerosols. Patients become infectious 2–3 days before the onset of symptoms, and persons with asymptomatic infections are also infectious. COVID-19 affects the upper respiratory tract, lungs (pneumonia, acute respiratory distress syndrome [ARDS]), heart, liver, gastrointestinal tract, and other organs. SARS-CoV‑2 uses ACE2 a receptor to enter host cells. Vasculitis, endothelial damage, thromboembolic events and organ failure are accompanied by a massive cytokine response. Elderly people and those with pre-existing diseases are particularly vulnerable. An efficient antiviral therapy is not yet available. Severely ill patients may benefit from dexamethasone and early treatment of complications. Candidate vaccines are currently being tested in clinical studies. |
format | Online Article Text |
id | pubmed-7456747 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Medizin |
record_format | MEDLINE/PubMed |
spelling | pubmed-74567472020-08-31 COVID-19: Epidemiologische und klinische Fakten Hemmer, Christoph J. Geerdes-Fenge, Hilte F. Reisinger, Emil C. Radiologe Leitthema Until July 31, 2020, about 17.6 million SARS-CoV‑2 infections and 680,000 deaths from COVID-19 were reported. SARS-CoV‑2 is most likely transmitted by droplets and probably by aerosols. Patients become infectious 2–3 days before the onset of symptoms, and persons with asymptomatic infections are also infectious. COVID-19 affects the upper respiratory tract, lungs (pneumonia, acute respiratory distress syndrome [ARDS]), heart, liver, gastrointestinal tract, and other organs. SARS-CoV‑2 uses ACE2 a receptor to enter host cells. Vasculitis, endothelial damage, thromboembolic events and organ failure are accompanied by a massive cytokine response. Elderly people and those with pre-existing diseases are particularly vulnerable. An efficient antiviral therapy is not yet available. Severely ill patients may benefit from dexamethasone and early treatment of complications. Candidate vaccines are currently being tested in clinical studies. Springer Medizin 2020-08-31 2020 /pmc/articles/PMC7456747/ /pubmed/32865603 http://dx.doi.org/10.1007/s00117-020-00741-y Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access Dieser Artikel wird unter der Creative Commons Namensnennung 4.0 International Lizenz veröffentlicht, welche die Nutzung, Vervielfältigung, Bearbeitung, Verbreitung und Wiedergabe in jeglichem Medium und Format erlaubt, sofern Sie den/die ursprünglichen Autor(en) und die Quelle ordnungsgemäß nennen, einen Link zur Creative Commons Lizenz beifügen und angeben, ob Änderungen vorgenommen wurden. Die in diesem Artikel enthaltenen Bilder und sonstiges Drittmaterial unterliegen ebenfalls der genannten Creative Commons Lizenz, sofern sich aus der Abbildungslegende nichts anderes ergibt. Sofern das betreffende Material nicht unter der genannten Creative Commons Lizenz steht und die betreffende Handlung nicht nach gesetzlichen Vorschriften erlaubt ist, ist für die oben aufgeführten Weiterverwendungen des Materials die Einwilligung des jeweiligen Rechteinhabers einzuholen. Weitere Details zur Lizenz entnehmen Sie bitte der Lizenzinformation auf http://creativecommons.org/licenses/by/4.0/deed.de (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Leitthema Hemmer, Christoph J. Geerdes-Fenge, Hilte F. Reisinger, Emil C. COVID-19: Epidemiologische und klinische Fakten |
title | COVID-19: Epidemiologische und klinische Fakten |
title_full | COVID-19: Epidemiologische und klinische Fakten |
title_fullStr | COVID-19: Epidemiologische und klinische Fakten |
title_full_unstemmed | COVID-19: Epidemiologische und klinische Fakten |
title_short | COVID-19: Epidemiologische und klinische Fakten |
title_sort | covid-19: epidemiologische und klinische fakten |
topic | Leitthema |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456747/ https://www.ncbi.nlm.nih.gov/pubmed/32865603 http://dx.doi.org/10.1007/s00117-020-00741-y |
work_keys_str_mv | AT hemmerchristophj covid19epidemiologischeundklinischefakten AT geerdesfengehiltef covid19epidemiologischeundklinischefakten AT reisingeremilc covid19epidemiologischeundklinischefakten |